This USP1 Target Evaluation Report is generated from PatSnap MCP data. USP1 is an early but strategically important DDR target for HRD and BRCA-mutant tumors, especially in combination with PARP inhibition or platinum chemotherapy.

This CHEK1 Target Evaluation Report is generated from PatSnap MCP data. CHK1 is a DNA-damage checkpoint target with meaningful clinical volume and a renewed biomarker angle through ACR-368 / prexasertib and OncoSignature-selected gynecologic cancers.

This ATR Target Evaluation Report is generated from PatSnap MCP data. ATR is one of the most clinically active DNA-damage-response targets, with 126 solid-tumor trials and 86 result records spanning PARP combinations, immunotherapy, ADC concepts, and replication-stress biomarkers.

This WEE1 Target Evaluation Report is generated from PatSnap Target & Disease MCP and Clinical Trials MCP data. In ovarian cancer, WEE1 inhibition has moved from DNA-damage checkpoint rationale into Phase 3 competition, led by azenosertib in CCNE1-positive platinum-resistant disease.

This MTAP Target Evaluation Report is generated from PatSnap MCP data. MTAP is best evaluated as a biomarker and synthetic-lethality context rather than a conventional drug target: direct MTAP-mapped drug counts are low, but Clinical Trials MCP found 46 MTAP-deletion trial records and PRMT5-related result records that make the MTAP-loss opportunity clinically important.

This SHP2 Target Evaluation Report is generated from PatSnap MCP data. PTPN11 / SHP2 is a central RAS/MAPK signaling node in NSCLC, with clinical development focused on KRAS G12C combinations, EGFR-mutant resistance, and pathway-feedback suppression.

This SOS1 Target Evaluation Report is generated from PatSnap MCP data. SOS1 is a RAS pathway target with active early clinical competition in KRAS-mutant tumors, but Clinical Trials MCP did not return released result records for the selected SOS1 solid-tumor query, making this a high-interest but still readout-light target.

This WRN Target Evaluation Report is generated from PatSnap MCP data. WRN is an emerging synthetic-lethality target for MSI-H and dMMR tumors, with early clinical programs now testing whether Werner helicase inhibition can convert a strong genetic dependency into a therapeutic class.

This PRMT5 Target Evaluation Report is generated from PatSnap Target & Disease MCP and Clinical Trials MCP data. The report highlights PRMT5 as a clinically active oncology target, especially in MTAP-deleted tumors where MTA-cooperative PRMT5 inhibition has created a differentiated synthetic-lethality strategy.

This CDK2 Target Evaluation Report is generated from PatSnap MCP data. CDK2 is an increasingly important cell-cycle target in breast cancer, especially for HR+/HER2- disease after CDK4/6 inhibitor exposure and for tumors with cyclin E or CCNE1-driven biology.

This GPRC5D Target Evaluation Report is generated from PatSnap MCP data. In multiple myeloma, GPRC5D has become a major post-BCMA and BCMA-adjacent target, with 110 Clinical Trials MCP trial records and 143 result records spanning bispecific antibodies, cellular therapies, and safety-management strategies.

This ROR1 Target Evaluation Report is generated from PatSnap Target & Disease MCP and Clinical Trials MCP data. ROR1 is an oncology target with compelling tumor-associated expression and active clinical exploration in CLL, but the evidence base is still earlier and more selective than mature hematology targets.